Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

36 results about "Leucine/Phenylalanine" patented technology

The other nine must be consumed (usually as their protein derivatives), and so they are called essential amino acids. The essential amino acids are histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine (i.e. H, I, L, K, M, F, T, W, V).

Process for preparing non-proteinogenic L-amino acids

Process is provided for preparing a non-proteinogenic L-amino acid by means of an enzymic biotransformation in which O-acetyl-L-serine is reacted with a nucleophilic compound, while using an O-Acetyl-L-serine sulfhydrylase as catalyst, to give a non-proteinogenic L-amino acid. The process is carried out at a pH in the range between pH 5.0 and 7.4.
Owner:WACKER CHEM GMBH

Carboline carboxylic acid-tetrapeptide conjugate and synthesis method as well as medical application thereof

The invention discloses a carboline carboxylic acid-tetrapeptide conjugate and a synthesis method as well as application thereof used as an antithrombotic agent. In the invention, tri-carboxyl of 3S-1,2,3,4-tetrahydro-Beta-carboline-3-carboxylic acid with antithrombotic activity is conjugated with the ammonia end of AA-Tyr-Ser-Val tetrapeptide to obtain a finished product after deprotection, wherein AA is selected from alanine, glycine, proline, glutamine, leucine, phenylalanine, isoleucine, valine, tyrosine, tryptophane, histidine, asparaginate, aspartate, glutamate, serine, threonine, methionine, lysine or arginine residue. The evaluation experiment on a thrombotic model of a rat shows that the compound of the invention has excellent antithrombotic activity and can be applied as the antithrombotic agent. In addition, the invention can overcome the defect of low bioavailability caused by low solubility of the 3S-1,2,3,4-tetrahydro-Beta-carboline-3-carboxylic acid in polar solvents and non-polar solvents.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Metal surface protective film forming agent and use thereof

The present invention provides a metal surface protective film-forming agent that contains an α-amino acid (e.g., leucine, phenylalanine and valine) and a metal polishing solution using the same. The present invention also provides a method of polishing a surface of a base material for the manufacture of a substrate for semiconductor circuits, a method of forming a metal surface protective film, the use of the particular amino acid to the metal surface protective film forming agent, a substrate for semiconductor circuit that uses the same, a semiconductor circuit including these and a method of manufacturing the same.
Owner:AJINOMOTO CO INC

Antimicrobial peptide Ea-CATH1 of Equus asinus and genes and application thereof

The invention relates to an antimicrobial peptide Ea-CATH1 of Equus asinus and genes and applications thereof, belonging to the technical field of biological medicine. Ea-CATH1 is one genetic coding straight-chain polypeptide of Cathelicidin of Equus asinus, and the complete sequence of Ea-CATH1 is as follows: lysine-arginine-arginine-glycin-serine-valine-threonine-threonine-arginine-tyrosine-glutamine-phenylalanine-leucine-methionine-isoleucine-histidine-leucine-leucine-arginine-proline-lysine-lysine-leucine-phenylalanine-alanine. The gene coding Ea-CATH1 precursor is composed of 550 nucleotides and the part coding mature peptide is the 391-465th nucleotides. Ea-CATH1 has smaller molecular weight, stronger bactericidal effect and broader spectrum and extremely strong killing effect on various clinical drug-resistance bacteria; Ea-CATH1 has simple structure, does not contain disulfide bond and ring structure and is suitable to be prepared by chemical synthesis and gene engineering; and Ea-CATH1 also has useful characteristics such as no hemolysis and ultrastrong serum stability.
Owner:DALIAN UNIV OF TECH

Cyclodextrin glycosyl transferase with improved maltodextrin substrate specificity and preparation method thereof

The invention discloses a cyclodextrin glycosyl transferase with improved maltodextrin substrate specificity and a preparation method thereof and belongs to the fields of genetic engineering and enzyme engineering. According to the invention, for CGTase derived from peanibacillus macerans, lysine at a 47th site, tyrosine at a 89th site, asparaginate at a 94th site and aspartic acid at a 196th site are respectively mutated into leucine K47L, phenylalanine Y89F, praline N94P and tyrosine D196Y, so that AA-2G yields are respectively increased by 30.7%, 10.9%, 10.0% and 31.7%. Complex mutation is carried out on the mutant strains to obtain double mutants namely K47L / Y89F, K47L / N94P, K47L / D196Y, Y89F / N94P, Y89F / D196Y and N94P / D196Y, three-point mutants namely K47L / Y89F / N94P, K47L / Y89F / D196Y, K47L / N94P / D196Y and Y89F / N94P / D196Y and a four-point mutant namely K47L / Y89F / N94P / D196Y. Yields of AA-2G produced by the mutants while maltodextrin is utilized as a glycosyl donor are respectively increased by 42.6%, 11.0%, 37.6%, 43.6%, 43.6%, 41.6%, 44.5%, 50.5%, 20.8%, 35.6% and 64.4%. Compared with the wild type CGTase, the mutants is more beneficial to production of the AA-2G while the maltodextrin is utilized as the glycosyl donor.
Owner:JIANGNAN UNIV

Modulators of beta-amyloid peptide aggregation comprising D-amino acids

Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.
Owner:PRAECIS PHARM INC

Preparation method of targeting tumor vasculature Anxa1 marked precursor NOTA-IF7

The invention relates to a preparation method of targeting tumor vasculature Anxa1 marked precursor NOTA-IF7, which belongs to the fields of organic chemistry and medicines. According to the invention, a double-function chelating agent 1,4,7-triazacyclononane-1,4,7- triaceticacid (1,4,7-triazacyclononane-1,4,7- triaceticacid, p-SCN-Bn-NOTA, NOTA for short) is coupled with specifically combined tumor vasculature 7 peptide amino acid (isoleucine-phenylalanine-leucine-leucine-tryptophan-glutamine-arginine, IF7), and a HPLC one-step method is used for purifying to obtain NOTA-IF7. THE preparation method of NOTA-IF7 is simple, the reaction condition of the technology is mild, the yield is high, the product can be used for isotope mark of fluorine-18, copper-64 and gallium-68, and is conveniently prepared to a positron photographic developer for tumor.
Owner:蒋孟军 +4

Peptide for promoting insulin release of frog and its use in production of drugs

A non-finger scent frog insuline releasing stimulating peptide and use in pharmacy are disclosed. The stimulating peptide is prepared by separating from non-finger scent frog skin secretory liquid, purifying, determining its sequence and synthesizing polypeptide. It belongs to a single-chain polypeptide with molecular weight 2632.3 and isoelectric point 10.32. Polypeptide total sequence is phenylalanine-leucine-proline-leucine-lecucine-lactamic acid-glycine-leucine-lactamic acid-lactamic acid-agedoite-phenylalanine-leucine-proline-lysine-leucine-phenylalanine-cystecoside acid-lysine-isoleucine-threonine-arginine-lysine-glycine. It can improve insuline release, has excellent hemolytic and plasma clotting activities. It can be used to treat diabetes.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI

Rana nigromaculata antimicrobial peptide as well as gene and application thereof

The invention relates to a rana nigromaculata antimicrobial peptide as well as a gene and application thereof, and belongs to the technical field of biomedicine. The rana nigromaculata antimicrobial peptide is a gene coded single-chain polypeptide separated from an amphibian rana nigromaculata of China, wherein the molecular weight is 1,647.02 Daltons, and the isoelectric point is 11.05; and the complete sequence of the rana nigromaculata antimicrobial peptide is phenylalanine-isoleucine-proline-leucine-valine-serine-glycine-leucine-phenylalanine-serine-arginine-leucine-leucine-glycine-lysine. The coded gene of the rana nigromaculata antimicrobial peptide consists of 316 nucleotides, wherein the mature coded part of the coded gene contains 142nd-186th nucleotides. The artificially synthesized rana nigromaculata antimicrobial peptide has a strong antibacterial effect, has the advantages of high safety, simple sequence and convenience in synthesis, and can be used as a novel anti-infective agent for application.
Owner:KUNMING UNIV OF SCI & TECH

Modulators of β-amyloid peptide aggregation comprising D-amino acids

Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3–5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.
Owner:PRAECIS PHARM INC

Method for the fermentative production of l-amino acids

The present invention provides a bacterium of the genus Corynebacterium, in particular of the species Corynebacterium glutamicum, having the ability to excrete an L-amino acid selected from proteinogenic L-amino acids and L-omithine and new measures for the fermentative production of proteinogenic L-amino acids and L-ornithine by such bacteria.
Owner:EVONIK OPERATIONS GMBH

Didanosine pro-medicament and preparation method thereof

The invention belongs to the technical field of medicaments, and discloses a substituted L-amino acid ester pro-medicament of an anti-AIDS medicament-didanosine and a preparation method thereof. The invention performs purposeful structural modification on the didanosine, ensures that the didanosine is combined with different amino acids, and designs and synthesizes a compound of a (I) structure, namely a didanosine pro-medicament. Compared with oral didanosine, the bioavailability of the compound is obviously improved and is equivalent to that of intravenously administrable didanosine. The pro-medicament and the preparation method are expected to develop a carrier pro-medicament with better therapeutic effect for treating AIDS. In the (I), R is L-type amino acid residue, and the L-type amino acid residue is preferably selected from L-valine, L-isoleucine, L-phenylalanine, L-proline and L-tryptophan.
Owner:SHENYANG PHARMA UNIVERSITY

Antimicrobial peptide compositions for plants

Compositions containing one or more tyrocidines, tryptocidines, phenycidines and / or gramicidin S, or derivatives and analogues thereof, are described for controlling antimicrobial growth on plants, plant material or plant growth media, and methods for controlling or preventing the growth of microbial pathogens, and in particular fungal pathogens, on plants, plant parts and plant material are described herein. The active agents used to control these pathogens are tyrocidines, tryptocidines, phenycidines and / or gramicidin S, or derivatives, analogues or modifications thereof. The tyrocidines, tryptocidines, phenycidines and / or gramicidin S are cyclic decapeptides having the general amino acid sequence cyclo(valine-Xrleucine-D-phenylalanine-proline-X2-X3-X4-X5-X6) (SEQ ID NO: 1) or a derivative or analogue thereof, wherein X1 is ornithine or lysine, X2 is valine, leucine, isoleucine, phenylalanine, tryptophan or tyrosine; X3 is the D-isomer of valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, ornithine, or lysine; X4 is asparagine, glutamine or leucine; X5 is glutamine, the D-isomer of valine, leucine, or isoleucine; and X6 is tyrosine, phenylalanine, tryptophan or proline.
Owner:STELLENBOSCH UNIVERSITY

CTL epitope peptide on HTNV GP as well as screening method and application thereof

The invention discloses CTL epitope peptide on HTNV GP as well as a screening method and application thereof. The epitope peptide is composed of 8 amino acids: isoleucine-threonine-serine-leucine-phenylalanine-serine-leucine-leucine (ITSLFSLL), and the sequence position is GPaa 456-463; the screening method of the epitope peptide comprises the following steps of: prediction, synthesis and detection; and according to research, the epitope peptide can be applied to the stimulation of body cellullar immunologic response. The invention has the following beneficial effects: through the screening and killing ability detection of CTL epitope peptide on HTNV GP and in combination with abundant neutralizing epitopes of GP, the body can be stimulated to generate relatively strong neutralizing antibodies, the development of a novel multifunctional efficient peptide-fragment vaccine with neutralizing epitope and CTL epitope is facilitated, and the invention is of important significance to the research of a HTNV novel genetic engineering vaccine.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

The ctl epitope of hepatitis B virus core antigen and its related application

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.
Owner:海图生物科技(上海)有限责任公司 +1

Bean germ meal

The invention discloses bean germ meal. Every 100g of bean germ meal comprises the following components: 30-40mg of vitamin C, 6.4g of aspartic acid, 1.98g of tyrosine, 1.7g of valine, 1.6g of leucine, 1.5g of phenylalanine, 1.2g of isoleucine, 1.1g of lysine, 2.6g of threonine, 1.7g of arginine, 0.5g of methionine, 2.6g of proline, 2.0g of glutamic acid, 1.2g of alanine, 1.1g of serine, 0.8g of glycine, 0.6g of histidine and 0.5g of cystine. In the germination process of seeds, the protein of the seeds is hydrolyzed into amino acids which are favorable for being absorbed by the human body; and the bean germ meal is rich in vitamins, mineral substances such as potassium, calcium, iron and zinc as well as various amino acids necessary for the human body, so that the bean germ meal has the effects of inhibiting cancer cells, reducing blood fat, preventing and treating cardiovascular diseases, delaying senescence and the like.
Owner:张铭文

Non-proteinogenic L-amino acids

Process for production of non-proteinogenic L-amino acids by direct fermentation of a microorganism strain known per se having a deregulated cysteine metabolism in a manner known per se, which comprises adding, during the fermentation, a nucleophilic compound to the fermentation batch in a manner such that this leads to the production of non-proteinogenic L-amino acids by the microorganism strain.
Owner:WACKER CHEM GMBH

A kind of antibacterial and antifouling polymer brush and its preparation method and application

The invention discloses an antibacterial and antifouling polymer brush as well as a preparation method and application thereof. The polymer brush is formed by a conjugate of polyethylene glycol and a polypeptide, wherein one end of the polyethylene glycol is fixed on a solid surface; the polypeptide is composed of 3-6 hydrophobic amino acids; the hydrophobic amino acid is selected from leucine one or more of acid, phenylalanine, valine, and isoleucine. The antibacterial and antifouling polymer brush of the present invention combines polypeptide and polyethylene glycol, which not only endows the solid surface with antibacterial performance, but also has obvious antifouling effect. Compared with ordinary antibiotics, the antibacterial and antifouling polymer brush of the present invention does not produce drug resistance while being antibacterial, and is suitable for various solid surfaces, has wide applicability, and has a wide range of applications in biomedical materials. Application prospects.
Owner:TECHNICAL INST OF PHYSICS & CHEMISTRY - CHINESE ACAD OF SCI

Peiminine derivative and preparation method and application thereof

The invention relates to a peiminine derivative and a preparation method and application thereof, and belongs to the field of medicinal chemistry. The preparation method comprises the following steps: dissolving 3-furancarboxylic acid, 2-naphthoic acid, 3-indoleacetic acid, Boc-valine, Boc-leucine, Boc-tryptophan, Boc-glycine, Boc-isoleucine, Boc-phenylalanine, Boc-alanine, other organic acids and 4-dimethylaminopyridine in dichloromethane, standing for 10 minutes at room temperature, adding peiminine, and finally adding 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride EDC.HCl, and reacting at room temperature for 6 hours to obtain 10 kinds of peiminine derivatives. Activity verification shows that the derivatives have a good anti-tumor effect. The preparation method disclosed by the invention has the advantages of simplicity, safety, high conversion rate, few byproducts and the like, has a good development prospect, and lays a theoretical foundation for later research.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Method and special culture medium for SILAC labelling of mycobacterium smegmatis protein

The invention discloses a special culture medium for SILAC labelling of a mycobacterium smegmatis protein. The culture medium for SILAC labeling is composed of inorganic salts, histidine hydrochloride, isoleucine, valine, leucine, phenylalanine, tryptophan, serine, multi-stable isotope labelled lysine, multi-stable isotope labelled arginine, threonine, tyrosine, methionine, adenine sulfate, uraciland glucose. The inorganic salts comprise ammonium sulfate, sodium citrate, disodium hydrogen phosphate, potassium dihydrogen phosphate, ammonium ferric citrate, magnesium sulfate, calcium chloride,zinc sulfate and copper sulfate. Experiments prove that the culture medium for SILAC labelling of the mycobacterium smegmatis protein can label the mycobacterium smegmatis protein efficiently within 10 generations, and creates conditions for preparation of quantitative internal standards and efficient and accurate comparative study of quantitative proteome.
Owner:BEIJING PROTEOME RES CENT

Engineering monoclonal antibodies to improve stability and production titer

Provided herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and / or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.
Owner:AMGEN INC

CTL epitope of hepatitis B core antigen and related application of CTL epitope

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.
Owner:海图生物科技(上海)有限责任公司 +1

Non-proteinogenic L-amino acids

Non-proteinogenic L-amino acids produced by direct fermentation of a microorganism strain known per se having a deregulated cysteine metabolism in a manner known per se, which comprises adding, during the fermentation, a nucleophilic compound to the fermentation batch in a manner such that this leads to the production of non-proteinogenic L-amino acids by the microorganism strain.
Owner:WACKER CHEM GMBH

bmspi39 mutants and their applications

The invention belongs to the technical field of genetic engineering and enzyme engineering, and specifically relates to BmSPI39 mutant and application thereof. BmSPI39 is composed of the 25th to 98th positions in SEQ ID NO.1. The BmSPI39 mutant is the amino acid sequence of BmSPI39, as shown in SEQ ID NO.1, the alanine at the 56th position is mutated to arginine, Lysine, Serine, Threonine, Glutamine, Tyrosine, Methionine, Leucine, Aspartic Acid, Glutamic Acid, Histidine, Cysteine, Valine, Astragalus Paragine, Isoleucine, Phenylalanine, Tryptophan, Proline or Glycine. The BmSPI39 mutants of the present invention all have inhibitory activity on subtilisin and elastase, and when mutated to arginine or lysine, they also obtain trypsin inhibitory activity, and such mutants can be used to prepare trypsin inhibitors , the application prospect is good.
Owner:SHAANXI SCI TECH UNIV

Polysaccharide magnetic resonance and fluorescence dual-mode imaging diagnostic agent and preparation method thereof and diagnostic reagent

The invention belongs to the technical field of medicine and chemistry, and particularly relates to a polysaccharide magnetic resonance and fluorescence dual-mode imaging diagnostic agent and a preparation method thereof and a diagnostic reagent. The diagnostic agent is prepared from pentapeptide (tyrosyl-isoleucyl-glycyl-seryl-arginine, YIGSR) containing a rhodamine B group and nonapeptide tryptophan-isoleucine-phenylalanine-proline-tryptophan-isoleucine-glutamine-leucine-lysine, WIFPWIQL) derivative is used as a tumor targeting property, a fluorescence imaging group and a polysaccharide macromolecular compound containing open-chain or cyclic polyaminopolycarboxylic acid in a side chain are coupled into a ligand through a chemical reaction, the ligand reacts with paramagnetic metal ions to form a paramagnetic metal complex, and the diagnostic agent can be used for magnetic resonance (MRI)-fluorescence dual-mode imaging and other medical imaging diagnosis of tumors in human bodies or other mammals.
Owner:WUHAN INSTITUTE OF TECHNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products